Casdin Capital, LLC - DENALI THERAPEUTICS INC ownership

DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 110 filers reported holding DENALI THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is 1.27 and the average weighting 0.7%.

Quarter-by-quarter ownership
Casdin Capital, LLC ownership history of DENALI THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$26,819,000
-30.1%
1,300,0000.0%2.97%
-11.5%
Q2 2023$38,363,000
+28.1%
1,300,0000.0%3.35%
+35.9%
Q1 2023$29,952,000
-17.2%
1,300,0000.0%2.47%
-11.9%
Q4 2022$36,153,000
+18.4%
1,300,000
+30.7%
2.80%
+39.6%
Q3 2022$30,537,000
-30.8%
995,000
-33.7%
2.01%
-46.3%
Q2 2022$44,145,000
-8.5%
1,500,0000.0%3.73%
+72.5%
Q1 2022$48,255,000
-27.9%
1,500,0000.0%2.16%
+14.7%
Q4 2021$66,900,000
-22.0%
1,500,000
-11.8%
1.89%
-11.7%
Q3 2021$85,765,000
-32.1%
1,700,000
+5.6%
2.14%
-33.4%
Q2 2021$126,288,000
+37.4%
1,610,0000.0%3.21%
+17.1%
Q1 2021$91,931,000
-16.2%
1,610,000
+22.9%
2.74%
-15.8%
Q4 2020$109,726,000
+133.8%
1,310,0000.0%3.25%
+54.7%
Q3 2020$46,937,000
+48.2%
1,310,0000.0%2.10%
+12.1%
Q2 2020$31,676,000
+24.3%
1,310,000
-10.0%
1.88%
-30.7%
Q1 2020$25,477,000
+17.0%
1,455,000
+16.4%
2.70%
+35.1%
Q4 2019$21,775,000
-99.8%
1,250,000
+92.3%
2.00%
+94.2%
Q3 2019$9,958,000,000
+19.9%
650,000
+62.5%
1.03%
+32.7%
Q2 2019$8,304,000,000
+357522.7%
400,000
+300.0%
0.78%
+204.7%
Q1 2019$2,322,000
+12.4%
100,0000.0%0.26%
-27.8%
Q4 2018$2,066,000100,0000.35%
Other shareholders
DENALI THERAPEUTICS INC shareholders Q4 2019
NameSharesValueWeighting ↓
Crestline Management, LP 19,462,500$339,037,00035.95%
Euclidean Capital LLC 323,749$27,117,0005.74%
Flagship Pioneering Inc. 2,730,263$228,687,0004.16%
Casdin Capital, LLC 1,310,000$109,726,0003.25%
A.R.T. Advisors, LLC 6,173$517,0002.39%
MARK ASSET MANAGEMENT LP 172,040$14,410,0001.73%
Temasek Holdings (Private) Ltd 4,410,457$369,420,0001.59%
Integral Health Asset Management, LLC 57,500$4,816,0001.43%
GILDER GAGNON HOWE & CO LLC 3,219,843$269,694,0001.34%
IRONWOOD INVESTMENT MANAGEMENT LLC 19,365$1,622,0000.95%
View complete list of DENALI THERAPEUTICS INC shareholders